Table 1.
Hypertensive animal strains in which suppression of immunity/inflammation ameliorated or prevented hypertension
| Blood Pressure, mmHg |
|||
|---|---|---|---|
| Strain | Experimental Strategy/Treatment | Untreated | Treated |
| Spontaneously hypertensive rat (SHR) | Cyclophosphamide (132) | 172 | 153 |
| Mycophenolate mofetil (222) | 198 | 147 | |
| Inhibition of NFκB activation (218) | 198 | 127 | |
| Suppression of oxidative stress (189) | 195 | 149 | |
| (223) | 207 | 179 | |
| (316) | 175 | 149 | |
| Stroke-prone SHR | Increase CD4+CD25+Foxp3 cells (Treg cells) by sympathetic denervation (128) | 175 | 150 |
| Dahl’s salt sensitive rat | Inhibition of pyrimidine synthesis (283) | 250 | 200 |
| Mycophenolate mofetil (174) | 139* | 122* | |
| Tacrolimus (52) | 170* | 150* | |
| Tempol (52) | 140* | 126* | |
| Etanercept (104) | 165* | 145* | |
| Anti-TGF-β antibody (44) | 190* | 177* | |
| (187) | 200* | 179* | |
| Anti-IL-6 antibody (94) | 149* | 138* | |
| Genetic deletion of p67phox (69) | 180* | 140* | |
| Mesenchymal stem cell transplantation (103) | 185* | 150* | |
| Mutation of RAG 1 gene (175) | 180* | 150* | |
| Deletion of the CD247 gene (225) | 151* | 134* | |
| Mutation in the SH2B3 gene (226) | 175* | 135* | |
| Lyon rat | Neonatal thymectomy (8) | 122 | 111 |
| Cyclophosphamide (9) | 175 | 135 | |
| Fawn Hooded rat | Inhibition of NFκB activation (137) | 159 | 128 |
| dTGF rat | Inhibition of NFκB activation (185) | 185 | 162 |
| Cyclosporine A (180) | 210 | 178 | |
| Inhibition of p38 MAPK (204) | 203 | 165 | |
| NZB mice | Cyclosporine A (263) | 155* | 147* |
| NZBW mice | Anti-IL-4 antibody (285) | 87* | 68* |
| Rosiglitazone (291) | 139* | 127* | |
| Etanercept (290) | 150* | 130* | |
| Anti-CD20 antibody (170) | 141* | 127* | |
Data are systolic blood pressure or mean arterial pressure (*).
There is considerable variation in the antihypertensive effect of the various treatments. Reference numbers are given in parentheses. See text for definitions.